Abstract:Cardiovascular complications are the leading cause of morbidity and mortality in patients with diabetes mellitus; up to 80% of deaths in patients with diabetes are closely associated with vascular disease. The ability of the organism to form a collateral network of blood vessels constitutes an important response to vascular occlusive disease and determines to a large part the clinical consequences and severity of tissue ischemia. The development of new vessels is significantly reduced in diabetic patients with coronary or peripheral artery disease. This probably contributes to the severe course of limb ischemia in diabetic patients, in which peripheral artery disease often results in foot ulceration and lower extremity amputation. Diabetic retinopathy remains one of the major causes of acquired blindness in developed nations. This is true despite the development of laser treatment, which can prevent blindness in the majority of those who develop macular edema or proliferative diabetic retinopathy. The hallmark of diabetic retinopathy is the lack of microvessels in the macula, leading to hypoxia, associated with peripheral retinal neovascularization that may ultimately cause severe vitreous cavity bleeding and/or retinal detachment. The factors that stimulate retinal blood vessel growth have not been fully defined, but there is accumulating evidence that the renin-angiotensin-bradykinin system may be involved in a number of retinal vascular disorders, including retinopathy of prematurity and proliferative diabetic retinopathy. Only a few studies have specifically evaluated the effect of diabetes on angiogenesis in ischemic vascular disease and in the retina. Moreover, the mechanisms by which diabetes could both limit the formation of new blood vessels in most organs and simultaneously induce proliferative diabetic retinopathy remain largely undefined. In the present review, we aimed to briefly describe the main molecular mechanisms involved in the ischemia-induced angiogenesis, and their alterations in diabetes. Possible therapeutic strategies to restore angiogenesis in diabetic patients are also listed.

In Vitro Models of Diabetes: Focus on Diabetic Retinopathy

Diabetic Retinopathy: From Animal Models to Cellular Signaling

An In Vitro Model of Diabetic Retinal Vascular Endothelial Dysfunction and Neuroretinal Degeneration

Current understanding of the molecular and cellular pathology of diabetic retinopathy

Rodent Models of Diabetic Retinopathy as a Useful Research Tool to Study Neurovascular Cross-Talk

Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction

The Role of Angiogenesis in the Development of Proliferative Diabetic Retinopathy: Impact of Intravitreal Anti-VEGF Treatment

Review on In-vitro Techniques and In-vivo Animals Models for Screening Diabetes and Diabetic Complications

Cell and molecular targeted therapies for diabetic retinopathy

Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform

Diabetic Retinopathy: Vascular and Inflammatory Disease

Modeling early pathophysiological phenotypes of diabetic retinopathy in a human inner blood-retinal barrier-on-a-chip

The progress in understanding and treatment of diabetic retinopathy

Progress in experimental models to investigate the in vivo and in vitro antidiabetic activity of drugs

Choosing Preclinical Study Models of Diabetic Retinopathy: Key Problems for Consideration.

Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms

Emerging drugs for the treatment of diabetic retinopathy

[Diabetes and peripheral arterial occlusive disease: therapeutic potential and pro-angiogenic strategies]

Molecules related to diabetic retinopathy in the vitreous and involved pathways

Recent advances in the treatment and delivery system of diabetic retinopathy

A New Human Blood–Retinal Barrier Model Based on Endothelial Cells, Pericytes, and Astrocytes